Jagiellonian University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Crakow Poland (1364)

Organization Overview

First Clinical Trial
2001
NCT00558155
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Angiology Department, Jagiellonian University Medical College | Centre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College | Coronary Disease Department - Jagiellonian University medical College - Krakow (Poland) | Department of Clinical Nursery, Jagiellonian University | Department of Coronary Disease, Institute of Cardiology, Jagiellonian University Medical College | Department of Internal Medicine and Gerontology - Jagiellonian University Medical College - Krakow (Poland) | Insitute of Cardiology Jagiellonian University Krakow | Institute of Cardiology Jagiellonian University Krakow | Jagellonian University, Krakow, Poland | Jagiellonian University | Jagiellonian University 1 Dept Surgery | Jagiellonian University Colegium Medicum | Jagiellonian University College of Medicine | Jagiellonian University Medical College | Jagiellonian University Medical College Krakow - I Cardiac Department - Krakow (Poland) | KCRI | Polish-American Children's Hospital | Radoslaw Pach, MD, Ph D

Active Ingredients

Drugs in Phase 4 Trials (11)

adalimumab (humira) (1 trial)

azithromycin (zithromax) (1 trial)

certolizumab pegol (cimzia) (1 trial)

etanercept (enbrel) (1 trial)

fish oil (Omegavan) (2 trials)

gabapentin (neurontin) (1 trial)

infliximab (remicade) (1 trial)

l-alanyl-l-glutamine (2 trials)

methylprednisolone (medrol) (1 trial)

metronidazole (flagyl) (2 trials)

reconvan (2 trials)

Drugs in Phase 3 Trials (14)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia) (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

albuterol (proventil) (1 trial)

cisplatin (platinol) (1 trial)

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (Kinrix) (1 trial)

docetaxel (taxotere) (2 trials)

fluorouracil (efudex) (2 trials)

Inactivated polio virus - Enhanced (IPOL) (1 trial)

irinotecan (Camptosar) (1 trial)

ivabradine (corlanor) (1 trial)

leucovorin (1 trial)

montelukast (singulair) (1 trial)

oxaliplatin (eloxatin) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (6)

cladribine (leustatin) (1 trial)

hyaluronic acid (3 trials)

nivolumab (opdivo) (1 trial)

obinutuzumab (gazyva) (1 trial)

rituximab (rituxan) (1 trial)

rostafuroxin (1 trial)

Drugs in Phase 1 Trials (3)

111in-cp04 (1 trial)

[99mtc]tc-tecant1 (1 trial)

gelofusin (1 trial)

Drugs in Other Trials (17)

bifidobacterium breve (1 trial)

bifidobacterium rhamnosus (1 trial)

bupivacaine (Exparel) (1 trial)

chlorhexidine (hibitane) (1 trial)

denosumab (prolia) (1 trial)

estradiol (progynon depot) (1 trial)

ezetimibe (zetia) (1 trial)

icosapent ethyl (vascepa) (1 trial)

indocyanine green (ic-green) (1 trial)

letrozole (femara) (2 trials)

lidocaine (xylocaine) (2 trials)

methotrexate (2 trials)

ofloxacin (floxin) (1 trial)

prednisone (meticorten) (1 trial)

ropivacaine (naropin) (2 trials)

simvastatin (zocor) (1 trial)

zinc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 4)

Arthritis, Psoriatic (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Atherosclerosis (Phase 3)

Carcinoma (Phase 1)

Carcinoma, Neuroendocrine (Phase 1)

Communicable Diseases (Phase 4)

Crohn Disease (Phase 4)

Essential Hypertension (Phase 2)

Hypertension (Phase 2)

Infections (Phase 4)

Ischemia (Phase 3)

Osteoarthritis, Knee (Phase 4)

Pain, Postoperative (Phase 4)

Peripheral Arterial Disease (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Spondylitis (Phase 4)

Spondylitis, Ankylosing (Phase 4)

Thyroid Diseases (Phase 1)

Thyroid Neoplasms (Phase 1)

Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 35
  • # of Trial APIs: 51